Poster Presentation NSW State Cancer Conference 2023

Using Metabolic ketosis to alter DNA Damage response and Cellular Senescence pathways during chemotherapy in Acute Leukemia patients (#322)

Gayathiri Rajakumar 1 2 , Maria Lastra Cagigas 1 2 , Stephen Fuller 1 3 , Kristen Skarratt 1 , Tiana Pelaia 1 2 , Rachael Hayward 1 , Alireza Ardjmand 1 4 , Luigi Fontana 2 5 6
  1. Nepean Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
  2. Charles Perkins Centre , Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
  3. Department of Haematology, Nepean Hospital, NBMLHD , Sydney, NSW, Australia
  4. Department of Haematology, Nepean Hospital, NSWP, Sydney, NSW, Australia
  5. Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, NSW, Australia
  6. Department of Clinical and Experimental Sciences, Brescia University School of Medicine, Brescia, Italy

Background: Chemotherapy targets rapidly proliferating cells- damaging both malignant and healthy cells. Chemotherapy-induced cellular damage to healthy tissue causes its notorious acute and chronic side effects. Preclinical data show that a ketotic state inhibits the insulin/IGF-1/mTOR pathway and induces cellular repair pathways, thereby protecting healthy cells. We hypothesise that, in humans, metabolic ketosis will provide chemo-protection to healthy cells by upregulating DNA repair and inhibiting cellular senescence, while sensitising cancer cells to chemotherapy by depriving them of their main energy source, glucose.

 Aim: To analyse the effects of a ketogenic diet alongside chemotherapy on healthy and leukemic cells in acute leukemia patients.

 Methods: Changes in markers of DNA repair, cellular senescence and proliferation were analysed using flow cytometry in healthy and cancer cells from patients pre-, during, and post-chemotherapy treatment.

 Results: Preliminary data at 24 and 48 hrs of chemotherapy showed increased y-H2AX expression in leukemic cells in subjects receiving a ketogenic diet (n = 3) compared to the control diet (n = 4). Furthermore, non-leukaemic T-cells from ketogenic subjects’ post-chemotherapy showed a decrease in the cellular senescence markers p16, p21 and SA β-galactosidase compared to control subjects. ATM, 53BP1 and p53 were minimally altered in both study arms.

 Conclusion: Preliminary data show that a ketogenic diet increases chemotherapy-induced DNA damage in leukaemic cells during chemotherapy, while it decreases cellular senescence markers in healthy lymphocytes post-treatment, highlighting the potential dual role of this diet as a first-line adjuvant and chemo-protective therapy.